Cohort

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer

Retrieved on: 
星期五, 五月 3, 2024
FDA, Congress, Cancer, Urinary tract infection, Urinary diversion, Safety, Carcinoma, Survival, Johnson & Johnson, Immunotherapy, CRS, Abstract, Cohort, BCG, Disease, Bladder cancer, Dysuria, Patient, Metastasis, Medicine, NMIBC, AUA, Biopsy, BTD, Urination, Interim, Food and Drug Administration, SAN, Pharmaceutical industry

SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of investigational TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ, who are ineligible for, or decline, radical cystectomy. These data were featured today in a plenary session (Abstract #P2-01) at the 2024 American Urological Association Annual Meeting (AUA) taking place May 3-6, 2024, in San Antonio, Texas.

Key Points: 
  • "These results address an area of high unmet need for bladder sparing therapies in this patient population."
  • Results included an evaluation of 85 patients (median age of 71 years old: range 40-88; 32.9% with concurrent papillary disease) who received TAR-200 monotherapy.
  • The centrally confirmed complete response (CR) rate was 82.8% by urine cytology and/or biopsy (95% confidence interval [CI], 70.6-91.4).
  • Seven patients (8.2%) had Grade 3 or higher TRAEs and four patients (4.7%) had one or more serious TRAEs.

Latinas & Power Corp. Celebrates Successful Launch and Expansion of Latinas in Leadership Institute

Retrieved on: 
星期一, 四月 29, 2024
Greater New Haven, Voya Financial, Equity, Community foundation, Lili, Woman, Health equity, Liberty Bank, Partnership, Cohort, Women's History Month, Curriculum, Culture, Power Corporation of Canada, AARP, Community development, Government, Leadership Institute, Management

HARTFORD, Conn., April 29, 2024 /PRNewswire/ -- Latinas & Power Corp. announced the successful launch and expansion of the Latinas in Leadership Institute (LiLi), a groundbreaking virtual program designed to empower Latina professionals and entrepreneurs in Connecticut, Massachusetts and beyond. With generous financial support from private, government, and foundation sectors, Latinas & Power Corp. has been able to secure the necessary funding to establish and grow this transformative initiative. "This investment will build capacity for a meaningful development opportunity for Latina leaders around New England," said Braeden Mayrisch, VP, Equity and Impact at Voya Financial and VP, Voya Foundation, "The Latinas in Leadership Institute provides our participants with an opportunity to invest in skill-building for themselves and their employers, while finding meaningful ways to give back to the Hartford Region."

Key Points: 
  • HARTFORD, Conn., April 29, 2024 /PRNewswire/ -- Latinas & Power Corp. announced the successful launch and expansion of the Latinas in Leadership Institute (LiLi), a groundbreaking virtual program designed to empower Latina professionals and entrepreneurs in Connecticut, Massachusetts and beyond.
  • Marilyn Alverio, Executive Director of the Institute and CEO of Latinas & Power Corp., stated "The impact has been tremendous."
  • Investing in expanding programs, reaching more beneficiaries, and launching new initiatives is crucial for the long-term sustainability of Latinas & Power Corp.
  • For more information about the Latinas in Leadership Institute and how to get involved, please visit Latinas in Leadership Institute or contact the program manager: [email protected]

Aphaia Pharma Provides Enrollment and Protocol Update for Phase 2 Trial in Individuals with Obesity

Retrieved on: 
星期四, 四月 25, 2024
FDA, Safety, Food, Weight loss, Cohort, Obesity, Patient, DSM-IV codes, Metabolism, SAN, Pharmaceutical industry

The new protocol will include four additional cohorts, which will be dosed with either 6g (APHD-006) or 8g (APHD-008) of Aphaia’s formulation or their respective placebos twice per day.

Key Points: 
  • The new protocol will include four additional cohorts, which will be dosed with either 6g (APHD-006) or 8g (APHD-008) of Aphaia’s formulation or their respective placebos twice per day.
  • With the expansion of the protocol, Aphaia aims to leverage the beneficial effects of circadian timing, which are known to improve metabolic diseases and weight control.
  • The Phase 2 trial ( NCT05385978 ) is a randomized, double-blind, placebo-controlled, proof-of-concept study assessing the safety and efficacy of Aphaia’s oral glucose formulation in adults with obesity.
  • The study will also evaluate exploratory secondary endpoints, which are hallmarks of multiple metabolic diseases closely associated with obesity.

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

Retrieved on: 
星期一, 四月 15, 2024
Deviance (sociology), American Academy, Attention deficit hyperactivity disorder, Patient, Multi, FAAN, Nature, MDRI, Behavior, Communication, Sleep, Disease, AAN, Neurology, Cohort, ASA, Natural history, Pharmaceutical industry

NOVATO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced new data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome. Patients in Expansion Cohorts A & B treated with a set dose and regimen of GTX-102 showed rapid and clinically meaningful improvement across multiple domains consistent with or exceeding Dose-escalation Cohorts 4-7 data at Day 170. Treatment of the Dose-escalation Cohorts 4-7 showed long-term increasing and sustained clinical benefit far exceeding Natural History data at Day 758. These data will be discussed in more detail in a corporate presentation being hosted by the company today at 8:00 a.m. ET and will also be presented by Kemi Olugemo, M.D., FAAN at the 76th Annual American Academy of Neurology Meeting (AAN) in Denver on Tuesday, April 16.

Key Points: 
  • ET
    NOVATO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced new data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome.
  • Treatment of the Dose-escalation Cohorts 4-7 showed long-term increasing and sustained clinical benefit far exceeding Natural History data at Day 758.
  • Day 170 data were consistent with the treatment benefit observed in the Dose-escalation Cohorts at a similar timepoint.
  • “The totality of these interim data demonstrates that treatment with GTX-102 resulted in rapid, multi-domain improvements that continued during maintenance dosing.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

Retrieved on: 
星期三, 五月 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Doctor of Philosophy, PFS, Paranal Observatory, Table, License, Summit, Investment, ELCC, Progression-free survival, Research, Intraparenchymal hemorrhage, Immunotherapy, Trial of the century, Webcast, Cohort, Forecasting, PD-1, NGS, TKI, Patient, GRAIL, Brain, SMMT, Neoplasm, EGFR, VEGF, GAAP, Royal institute, Neuro, Lung cancer, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.
  • In January 2024, followed by a presentation at ELCC 2024 in March 2024, Akeso announced updates from its Phase II AK112-201 trial data.
  • Also at ELCC 2024, Summit and Akeso highlighted promising ivonescimab Phase II data in NSCLC patients with brain metastases.
  • Operating cash outflow for the three months ended March 31, 2024 and 2023 was $30.1 million and $13.1 million, respectively.

Treble Announces Creation of Artificial Intelligence Practice Group

Retrieved on: 
星期二, 四月 30, 2024
Security, Data Management, Other Communications, Technology, Public Relations, Investor Relations, Finance, Consulting, Fintech, Communications, Professional Services, Artificial Intelligence, Other Technology, Software, Internet, Mobile, Wireless, Marketing communications, Sambanova, News, AI, Marketing, Traction, SmartBear Software, API, Artificial intelligence, Cohort, Intelligence, VMware, History, IPO, Cision, Constructor, StackEngine, Silicon, Privacy, Initial public offering, LP record, Communication, Multimedia, Traffic light, San Francisco Bay Area, Partnership, Organization

Treble , a boutique public relations agency with 26 successful exits across its client portfolio, announced the formation of an Artificial Intelligence Practice Group today.

Key Points: 
  • Treble , a boutique public relations agency with 26 successful exits across its client portfolio, announced the formation of an Artificial Intelligence Practice Group today.
  • Treble Vice President Will Kruisbrink will lead up the new practice for the agency out of San Francisco.
  • View the full release here: https://www.businesswire.com/news/home/20240430651200/en/
    Will Kruisbrink, AI Practice Group lead at Treble (Photo: Business Wire)
    Treble collaborates with B2B technology-centric venture-backed companies, from seed-stage to pre-IPO and publicly traded companies.
  • “Artificial intelligence is foundational tech that will permeate nearly every industry,” said Ethan Parker , Founder and CEO at Treble.

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Retrieved on: 
星期三, 四月 10, 2024
FDA, Safety, Pharmacokinetics, Infrared spectroscopy correlation table, RECIST, CCNE1, Index, Cohort, Glioblastoma, Secondary, G12, MPH, WEE1, CCNE2, Serum, Aes, FBXW7, MD Anderson Cancer Center, ATR, Day, Pharmacodynamics, Pharmaceutical industry

DOYLESTOWN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today released details about four poster presentations at the ongoing American Association of Cancer Research (AACR) Annual Meeting, taking place April 5 to 10, 2024 in San Diego, CA. The posters feature APR-1051, Aprea’s next-generation inhibitor of WEE1 kinase, as well as a clinical update on ATRN-119, its novel macrocyclic ATR inhibitor. The Company also presented a poster highlighting a new set of preclinical data in glioblastoma with a next-generation macrocyclic ATR inhibitor, ATRN-333.

Key Points: 
  • Part 1 will be dose escalation and is expected to enroll up to 39 patients with advanced solid tumors harboring cancer-associated gene alterations.
  • ATRN-119 continues to be safe and well tolerated, with no dose-limiting toxicities and no signs of significant hematological toxicity reported.
  • Pharmacokinetic studies show ATRN-119 serum concentrations are entering the expected therapeutic range at the current highest dose level (550 mg).
  • Convection-enhanced delivery of a novel ATR inhibitor synergizes with systemic lomustine for improved treatment of glioblastoma.

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

Retrieved on: 
星期四, 四月 11, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Agreement, Patient, Cancer, Mutation, CDK9, Venetoclax, Colorectal cancer, MEI, Bevacizumab, AML, Research, Cohort, Salvage therapy, Disease, Exercise, Therapy, IDH, Incidence, Neoplasm, Toxicity, Acute myeloid leukemia, FLT3, Standard of care, Death, Clinical trial, VEGF, Calendar, Pharmaceutical industry

With the MEI Board aligned around our strategy, we have a productive framework to advance both clinical programs in a manner intended to address significant medical needs while prioritizing a measured and objective-based allocation of our resources,” said David Urso, president and chief executive officer of MEI Pharma.

Key Points: 
  • With the MEI Board aligned around our strategy, we have a productive framework to advance both clinical programs in a manner intended to address significant medical needs while prioritizing a measured and objective-based allocation of our resources,” said David Urso, president and chief executive officer of MEI Pharma.
  • The plan builds on encouraging recently reported voruciclib clinical data and ME-344 data separately reported today.
  • Under the plan, the ongoing voruciclib development strategy will be guided by future clinical trial results and applicable regulatory authority advice.
  • The goal of the formulation effort is to increase biological activity, improve patient convenience of administration and increase commercial opportunity.

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

Retrieved on: 
星期四, 四月 11, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, PFS, Patient, Safety, Sepsis, Progression-free survival, Survival, Bevacizumab, Glycolysis, Cohort, OXPHOS, Week, Fatigue, Neoplasm, Trial of the century, Overalls, Abdominal pain, Pharmaceutical industry

This landmark analysis exceeded the 20% threshold set in the Clinical Study Protocol to add an additional 20 patients to the study via the initiation of Cohort 2.

Key Points: 
  • This landmark analysis exceeded the 20% threshold set in the Clinical Study Protocol to add an additional 20 patients to the study via the initiation of Cohort 2.
  • The study was designed to evaluate ME-344 plus bevacizumab in up to two cohorts of approximately 20 patients each.
  • ME-344 in combination with bevacizumab at the dose and schedule evaluated was generally well tolerated with no overlapping toxicities observed.
  • Two patients (9%) discontinued therapy due to an adverse event: fatigue considered related to study drugs and sepsis considered unrelated.

IoTeX Announces DePIN Surf Demo Day for Cohort 1 on April 30th, 2024

Retrieved on: 
星期一, 四月 22, 2024
Knowledge, Decentralized finance, UN, Writing, Internet, AI, Mentorship, Software, Traction, Blockchain, SDK, Wi-Fi, TGE, Non-fungible token, Omniverse, Cohort, Carbon, V-Ray, Surf, Privacy, Trust (social science), Starpower, Generative, TEE, SAN, ZK, Cryptocurrency

SAN FRANCISCO, April 22, 2024 /PRNewswire-PRWeb/ -- IoTeX, a leading modular DePIN blockchain platform, announces Demo Day for Cohort 1 of DePIN Surf accelerator program on April 30, 2024.

Key Points: 
  • SAN FRANCISCO, April 22, 2024 /PRNewswire-PRWeb/ -- IoTeX , a leading modular DePIN blockchain platform, announces Demo Day for Cohort 1 of DePIN Surf accelerator program on April 30, 2024.
  • IoTeX, with support from FutureMoneyGroup and ForesightX, launched DePIN Surf, the first accelerator dedicated exclusively to supporting DePIN founders in January, 2024.
  • IoTeX , with support from FutureMoneyGroup and ForesightX , launched DePIN Surf, the first accelerator dedicated exclusively to supporting DePIN founders in January, 2024.
  • Cohort 1, which officially launched at the R3al World event at ETHDenver, features seven startups preparing for TGE and global launch.